about
US Renal Data System 2012 Annual Data Report.A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication managementComparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part DUtilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part DPatterns in blood pressure medication use in US incident dialysis patients over the first 6 months.Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort studySources of drug coverage among Medicare beneficiaries with ESRD.Introduction: chronic kidney disease: a burgeoning health epidemic.Chronic kidney disease and medicare.Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006Potential impact of Medicare Part D in the end-stage renal disease population.Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.Management of Polypharmacy in Dialysis Patients.A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.Sitagliptin--another option for managing type 2 diabetes in dialysis patients?Racial differences in clinical use of cinacalcet in a large population of hemodialysis patients.Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients.Erratum to: A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement report.Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patientsUtilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part DTrends in hip fracture rates in US hemodialysis patients, 1993-2010Lower risk of major cardiovascular events associated with adherence to colesevelam HCIIn reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'The authors reply
P50
Q30582337-AF97670B-F34D-4544-8B3B-4AEBAB5BFDEFQ31147535-BD10A883-5E08-4883-9F24-6FCF8A15CCEEQ33393880-667647CC-81EC-458C-BF95-1C4E97F50BD0Q33510868-1FFDA16B-8795-408F-A02B-2A9EA27FAC6AQ33577423-CD493BB5-688D-4603-84BF-78F2DE62FEF8Q33801022-0649D0B9-72CA-4C4E-99F8-A19D0C854E0CQ34403806-90DAB1F7-DD6E-444B-BE55-A85E356D8A8AQ35039319-774785FE-9BC2-4559-A398-B690A17C7E81Q35247578-08401A43-D767-45F6-897B-DDD547484D19Q35917495-35CC363A-7C00-4B33-8F51-C4A2231D7098Q37051279-488A9618-147E-4FBB-8F04-ED733A2AF75BQ37051287-0FAD99D6-7D3D-425A-9E21-6D1FE8457003Q37087904-52EDAB37-BC5D-457D-9BE1-F07C40ED3E84Q37107606-013935C1-0E24-4FB6-A328-673EF0529093Q37280811-44E7DB91-EDEE-4745-9C29-1AB3681BB7BCQ37957010-D0A12DA7-2737-492B-854C-D6FED9705580Q38098108-E57D0E4A-D22D-4021-B5BD-EF47DBA61BE5Q38416850-4FD6EB29-A72D-48CC-AED2-3DB6682376AFQ38741675-3D32FF1B-8EA3-4093-ACDD-782A1CFAF740Q43016416-9B39BC3C-D6EF-41D5-9D8C-E077CB723F40Q43447423-650F48F5-528D-4F20-918F-260A80F9EFA8Q44510554-E2380A8B-7F0F-49E6-8F2E-54D529E92755Q44658342-17559B8F-4EEF-4AEC-B9B1-6E000A0CA4D5Q46146529-AC384393-8E25-4EBB-A019-66204B613E53Q46581159-AE35223A-ED6C-40B9-BEFC-01CCBF0A6017Q48276101-177A6AFF-C607-4329-B07A-E461D67BA8A1Q50191241-E59B8585-BD1B-4686-BFF5-9F0021236EE8Q51719123-1B8BE1DE-A264-4C7B-A550-8598A3D6F1DCQ77308834-D1DB5D2E-0C4A-4FDE-8257-AD56C012E877Q83153065-5BECC39B-FC6B-4BC6-BE73-3D9364468A5CQ86693755-C8F73665-2663-4EF7-890B-395CEC7E229CQ86999566-528F2058-C60E-4749-BE88-F59EB3997FD2Q87302343-DB82CA10-1443-4801-A089-7DD764BB55D4Q95452822-22C9E4E2-0B1E-4F12-9406-A1136041898F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wendy St Peter
@ast
Wendy St Peter
@en
Wendy St Peter
@es
Wendy St Peter
@nl
Wendy St Peter
@sl
type
label
Wendy St Peter
@ast
Wendy St Peter
@en
Wendy St Peter
@es
Wendy St Peter
@nl
Wendy St Peter
@sl
prefLabel
Wendy St Peter
@ast
Wendy St Peter
@en
Wendy St Peter
@es
Wendy St Peter
@nl
Wendy St Peter
@sl
P106
P21
P31
P496
0000-0002-2201-3019